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patients. METHODS: The scale, which was translated into English from Turkish, 
again translated back into English by two independent translators, was applied to 32 
MSDs patiets for pre-test. Non working questions applied to a target group were re-
tested and then the scale was applied to the bulk of subjects (N  82). Cronbach’s 
Alfa was used to assess reliability and factor analysis to assess dimensionality. The 
EuroQol-5D was used for concurrent validity. RESULTS: Among the patients were 
15.9% ankylosing spondylitis, 6.1% rheumatoid arthritis, 24.4% osteoarthritis, 
12.2% osteoporosis, 13.4% radiculitis, 9.8% ﬁbromyalgia, 2.4% stroke, 15.9% rheu-
matic disease. The internal consistency coefﬁcient (Cronbach’s alpha) of SFS was 0.68. 
Factor analysis of the scale revealed that it was composed of three factors with Eigen-
values  1, accounting for 90.8% of the total variance. All items of the Turkish SFS 
had a factor load ranging from 0.40 to 0.77 There was a strong relationship between 
Social Functioning Scale and EuroQoL 5D. CONCLUSIONS: The Social Functioning 
Scale has good validity and reliability for Turkish MSDs patient.
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OBJECTIVES: Psoriatic arthritis (PsA) and rheumatoid arthritis (RA) are inﬂamma-
tory arthritis with signiﬁcant impact on patients’ health related quality of life (HRQL). 
The main goal of this study is to analyse the HRQL measures in these conditions. 
METHODS: Two cross sectional questionnaire surveys of consecutive patients with 
PsA (2008) and with RA (2004) were conducted in the same rheumatology outpatient 
centres in Hungary. Patients ﬁlled in the generic EQ-5D and the disease speciﬁc Health 
Assessment Questionnaire (HAQ), Psoriatic Arthritis Quality of Life Questionnaire 
(PsAQoL) / Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL). Assessing 
construct validity, patients were grouped by disease severity based on the yearly 
number of admissions to hospital, being on disability pension, use of devices and resort 
to help from others for everyday activities. The magnitude of difference between 
groups, the effect size was calculated as the standardized mean difference. Convergent 
validity was investigated by calculating the Spearman’s correlation between clinical 
scale variables and HRQL instruments. RESULTS: A total of 183 AP and 255 RA 
patients were enrolled. HRQL instruments’ scores were closer to the worse end of 
scales in case of severe PsA and RA, the highest effect size of each HRQL instrument 
was detected at use of home care. Strong correlations (rho  0.5) were observed 
between the EQ-5D, the PsAQoL / RAQoL, the HAQ disability score, the patient pain 
and global VAS. Disease duration of PsA and RA correlated weakly (rho  0.29) with 
all the HRQL instruments. CONCLUSIONS: Our results conﬁrm the good ability of 
EQ-5D, HAQ, PsAQoL/RAQoL to describe health state in PsA and RA. Our study is 
the ﬁrst to establish the correlation of HRQL instruments in PsA.
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OBJECTIVES: CZP 200 or 400 mg Q2W  methotrexate (MTX) signiﬁcantly 
improved HRQoL in patients with active RA over 1 year. Here we evaluated HRQoL 
in RA patients following long-term CZPMTX treatment. METHODS: Patients who 
completed 52 weeks treatment in RAPID 1 (completers) were eligible to enter an 
open-label (OL) study with CZP 400 mg Q2W  MTX. HRQoL was assessed using 
the SF-36 Survey that includes 8 domains (physical functioning [PF], role physical 
[RP], bodily pain [BP], general health [GH], vitality [VT], social functioning [SF], role 
emotional [RE] and mental health [MH]) grouped into summary scores: Physical (PCS) 
and Mental (MCS). MCIDs are 2.5 points for PCS/MCS and 5 for domain scores. 
Mean changes from baseline in HRQoL were analysed in completers at Week 100; 
domain scores were compared with US population norms (age/gender matched). 
RESULTS: CZP completers reported rapid and marked improvements in HRQoL at 
Weeks 12 (1st assessment) and 52 that were sustained to 100 weeks. Completers 
originally receiving CZP 200mg  MTX had mean PCS and MCS improvements of 
7.2 and 8.8 points, respectively, at Week 12, 9.1 and 8.2 points at Week 52, and 10.1 
and 7.7 points at Week 100; improvements were similar in patients originally receiving 
CZP 400 mg  MTX. Improvements in RE, GH and MH were sustained following 
long-term OL treatment, and met or exceeded MCID in PF, RP, BP and VT, which 
had the largest decrements at baseline. After 100 weeks of CZPMTX, BP, VT, SF 
and MH scores approached or met normative values. CONCLUSIONS: CZPMTX 
treatment results in rapid and clinically meaningful improvements in PCS, MCS and 
all SF-36 domains that were sustained over 2 years. BP, VT, SF and MH approached 
or met age/gender matched US population norms. Comparable beneﬁts were reported 
in RA patients enrolled in both CZP treatment arms.
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OBJECTIVES: Utility, one single value of quality of life ranged from 0 to 1, is known 
to differ between countries and available data in French population are sparse. This 
study reports on the effect of different fractures sites on self-reported EQ-5D in the 
post-menopausal osteoporosis population. METHODS: This cross-sectional study 
was carried out in general population by self completion questionnaire. Eligible 
women were those diagnosed for osteoporosis and aged 50 years and over. Utility was 
assessed using the index and VAS (range: 0–100) scores of the EQ-5D. For each group, 
the mean EQ-5D scores are reported. Univariate analysis on EQ5D index score permit-
ted to select covariables. As commonly used in health status studies, multivariate linear 
model including previous variables was performed in order to identify factors that 
most affected respondents’ EQ-5D scores. RESULTS: Questionnaires from a total of 
637 osteoporotic women were analysed. Among them, 228 already suffered a fracture. 
Last osteoporotic fracture sites reported were hip (N  22), vertebrae (N  45), wrist 
(N  80), rib (N  65), and others (N  16). Fractured women were older (mean age: 
70.3 o 8.1 vs 67.0 o 7.1 years; p  0.0001), had higher BMI values (p  0.0167) than 
others. When adjusted for age, the index and VAS scores of the EQ-5D were both 
signiﬁcantly different (p  0.01) between fractured (0.72 o 0.25; 68.3 o 16.46) and 
non fractured women (0.77 o 0.20; 72.3 o 14.82). Moreover, patient’s utility signiﬁ-
cantly decreased for hip and vertebral fractures with 0.114 and 0.102, respectively 
(p  0.01). However, loss of utility for patient with other fractures was not signiﬁcant 
(0.017; p  0.41). CONCLUSIONS: Both hip and vertebral fractures showed durable 
loss of utility, whereas other osteoporotic sites do not. Used for cost-utility analyses, 
mean QALYs of fractures for French osteoporotic population could be also 
calculated.
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OBJECTIVES: The impact of rheumatoid arthritis (RA) on patients’ work ability is 
well established. However, there is growing recognition of the impact on patients’ 
ability to perform household duties and social activities. This evaluates the impact of 
certolizumab pegol (CZP) plus methotrexate (MTX) on productivity within and 
outside the home in patients with active RA. METHODS: In RAPID1 and 2, produc-
tivity was assessed 4-weekly from baseline using the novel validated Work Productivity 
Survey (WPS-RA) that measures productivity limitations due to RA on work outside 
the home, household work and social activities. Mean changes from baseline in missed 
days of household work, days with reduced household productivity, missed days of 
family/social/leisure activities, self-reported work absenteeism and presenteeism (work 
days with productivity reduced by q50%) and RA impact on productivity a 0–10 scale 
(10  complete interference) were compared between treatment arms using non-para-
metric bootstrap-t methodology. RESULTS: A total 982 and 619 patients were ran-
domized into RAPID1, and 2, respectively. Baseline employment rates were 41.6% 
and 39.8%, respectively. The other patients included homemakers, retirees, those 
unable to work due to RA, and those unemployed for other reasons. Within each trial, 
treatment groups were comparable at baseline for productivity within and outside the 
home. In both trials, improvements in productivity within and outside the home were 
observed in the CZP arms as early as Week 4, and maintained until study end 
(RAPID1: 12 months, RAPID2: 6 months). In RAPID1, patients on CZP 200 mgMTX 
reported signiﬁcant decreases at Week 24 in days missed of household work (mean 
change 4.67 vs 1.54 days/month for MTX alone) and days with reduced productiv-
ity (mean change 5.68 vs 2.85 days/month for MTX alone). Similar improvements 
were reported with CZP 400 mgMTX and in RAPID2. Improvements in work pro-
ductivity and daily activities were reported. CONCLUSIONS: CZP improves produc-
tivity within and outside the home in RA patients.
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OBJECTIVES: To investigate the work related aspects of the burden of RA for 
patients. METHODS: A cross-sectional survey was conducted among working age 
RA patients (20 to 65 years old), members of one of the RA patients’ associations in 
France. The questionnaire was self-administered and used three validated instruments, 
the Health Assessment Questionnaire (HAQ), the EuroQoL-5 Dimension (EQ-5D) 
and the Working Productivity and Activity Impairment Questionnaire-RA (WPAI-
RA). RESULTS: A total of 3494 questionnaires were mailed and 1,189 (34.0%) could 
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be analysed. Mean age of patients was 53.1 years and the gender ratio (female to 
male) was 5.8. The mean duration of disease was 14.7 years. While at time of diag-
nosis, 83.6% of patients declared they were employed, the employment rate at the 
time of the survey was of 49.9%, 7 points lower than that of the French general popu-
lation adjusted for age and gender (p  0.001). A total of 38.3% declared to be on 
part-time job while this rate is only of 28.4% in the French general population (p  
0.05). 67.5% of patients who were or have been employed reported that the disease 
had a negative impact on their professional career (up to 92.6% for severe RA). The 
two main impacts reported were on their job choices and discrimination during their 
career. 61.4% considered that it resulted in income losses. The work productivity 
impairment was high (23.4% and up to 52.5% for severe RA, p  0.001) mostly due 
to impairment while working (presenteeism) rather than absenteeism. Finally, patients’ 
estimation of their RA-work income loss is about a600 per month, which is not com-
pensated by disability pensions (a223 per month on average). CONCLUSIONS: These 
results reﬂect both the objective and the subjective negative impact of RA on working 
status and conditions, even in a country with substantial social support and extensive 
health coverage.
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OBJECTIVES: To describe the disease management and the cost of patients presenting 
a diagnosis of low back pain in the hospital perspective. METHODS: We performed 
a local data base request from the medical information system (PMSI) of the university 
hospital of Montpellier. We considered 3 consecutive years (2006,2007,2008) which 
allow us to get a follow-up and a traceability of patients over this period. We analyzed 
a group of 18–50 years old patients admitted across acute care, day care or mid-term 
care sectors with the following diagnosis codes M 545, M 512 of the ICD-10. 
RESULTS: A total of 583 patients were selected over the period representing a total 
of 1674 admissions (i.e.: 2.8 admissions per patient). The mean o SD age was 39 o 8 
years and female represent 56% of the patients. We observed 195 admissions in acute 
care (“less than 24 h” admissions excluded) with a mean length of stay of 5 o 4.5 
days. Day-care represents 47% of the admission in acute care sector. We observed 
271 admissions in mid-term care with a mean length of stay of 8 o 5.8 days. Few 
patients (6.8 %) were admitted consecutively in acute care and in mid term care 
thereafter. Surgery was the reason of ﬁrst admission for 13 patients. The cost is esti-
mated at 1,391 euros per patient admitted in acute care sector. CONCLUSIONS: In 
our sample, we noted a high rate of admission per patient for diagnosis or physical 
therapy reasons as the main pattern of low back pain management in-hospital. Admis-
sions for surgery were marginal. Overview of real practices in-hospital sector is key 
information to determine the medical need in this active patient population. Innovative 
medical device would minimize the burden of disease by reducing the number of day 
lost in-hospital and the time to return to work.
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OBJECTIVES: To describe the disease management and the cost of patients presenting 
a diagnosis of lumbago-sciatica in the hospital perspective. METHODS: We per-
formed a local data base request from the medical information system (PMSI) of the 
university hospital of Montpellier. We considered 3 consecutive years (2006,2007,2008) 
which allow us to get a follow-up and a traceability of patients over this period. We 
analyzed a group of 18–50 years old patients admitted across acute care, day care or 
mid-term care sectors with the diagnosis code M 511 of the ICD-10. Distribution of 
DRG’s was also analyzed and a weighed calculation was performed for the cost per 
patient in acute care sector. RESULTS: A total of 503 patients were selected over the 
period representing a total of 598 admissions (i.e.: 1.18 admissions per patient). The 
mean o SD age was 39.2 o 7.4 years and female represent 42% of the patients. We 
observed 488 admissions in acute care (“less than 24 h” admissions excluded) with a 
mean length of stay of 6.4 o 4 days. Day-care represents 4.8% of the admission in 
acute care sector. We observed 5 admissions in mid-term care and few patients (0.6 
%) were admitted consecutively in acute care and in mid term care thereafter. 418 
patients underwent surgery during their stay in acute care sector. The cost is estimated 
at 3,751 euros per patient admitted in acute care sector. CONCLUSIONS: In this 
population of patient, surgery is the main pattern of care and the main driver of cost. 
Innovative medical device would minimize the burden of disease by reducing or delay-
ing the number of surgeries. Nevertheless, additional information from the ambulatory 
care sector would be useful to describe the complete lumbago-sciatica management 
and to deﬁne the medical need for innovations in this active patient population.
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OBJECTIVES: To describe Russian rheumatologists’ disease managment of ﬁbromy-
algic patients. In fact, the Fibromyalgia Syndrom (FMS) is a disorder characterized 
by widespread pain and fatigue, and causes signiﬁcant morbidity to patients and 
their relatives METHODS: The questionnaire was sent to a random sample of 
Russian practitioners, who were answering the same questionnaire as that used by 
French practitioners in 2003. RESULTS: Seventy-seven percent of the practitioners 
claimed that they prescribed a medical treatment to their patients suffering from 
ﬁbromyalgia. Forty percent prescribed antalgics, 40% prescribed tricyclic antidepres-
sants, 29% serotoninergic antidepressants, 30% hypnotics/sedatives, 8 % homeo-
pathic treatments and a little over 1% morphine derivatives. Sixty-seven percent 
claimed that they prescribed extra treatments for their patients suffering from ﬁbro-
myalgia: 23% prescribed antalgics, 20% prescribed tricyclic antidepressants, 17% 
serotoninergic antidepressants, 24% hypnotics/sedatives, 9% homeopathic treatments 
and less than 1% morphine derivatives. A total of 82.6 % recommended or prescribed 
other treatments to their ﬁbromyalgic patients, namely: 36% acupuncture, 56% 
physiotherapy, 14% hypnotherapy, 36% spa treatment, 3% osteopathy and 38% 
relaxation techniques. 91.8% of the doctors advised regular physical exercise such as 
swimming and walking (71.9% and 65.6% respectively), with cycling being the activ-
ity least often advised, by 12.9% of the doctors. CONCLUSIONS: Treatment for 
ﬁbromyalgia must be multidisciplinary and multifactorial, its main objective being 
relieving the patient of their symptoms and allowing them to return to their profes-
sional and leisure activities —to which treatment of the condition by Russian practi-
tioners is a testimony.
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OBJECTIVES: PMO (prevalence: 7–30%) increases the risk of fractures, reduces life 
quality and expectancy, leads to loss of employment and creates signiﬁcant health care 
costs. Poor clinical outcomes have been associated with lack of adherence to treatment. 
This analysis assesses PMO patient adherence to bisphosphonate therapy in Germany. 
METHODS: Applying a systematic review of literature utilizing German-based data, 
we identiﬁed and analyzed nine studies assessing adherence to oral bisphosphonates 
published between 2005 and 2009. Our analysis considered persistence and compli-
ance associated with daily and weekly dosing regimens. Compliance was deﬁned as 
Medication Possession Ratio (MPR) ³80%. RESULTS: Only 10% of PMO patients 
in Germany are currently treated with bisphosphonates. Between 31.3% and 46.0% 
of patients discontinued therapy after the ﬁrst prescription. Studies showed poor per-
sistence to bisphosphonate therapy during the ﬁrst year (43.2%). The persistence 
during the ﬁrst year was lower with daily dosing compared with weekly dosing 
regimen (27.8–42% vs. 46.5–57%, respectively). Patients’ compliance varied from 
41.7–58.2% over the ﬁrst year. Reasons identiﬁed for poor persistence and compliance 
included inconvenience and frequency of administration, imperceptible efﬁcacy, and 
lack of patient education on the need for the medication. Non-compliance was primar-
ily due to side effects. Overall, studies concluded that poor adherence leads to greater 
economic burden due to higher fracture rates and increased hospitalizations. CON-
CLUSIONS: A signiﬁcant proportion of PMO patients discontinued and/or did not 
comply with therapy during the ﬁrst year, likely due to dosage inconvenience and 
frequency, and side effects. There is a need for treatments that patients consider more 
convenient and are associated with fewer side effects.
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OBJECTIVES: The objective was to analyse the exposure to osteoporosis medication 
(OPM) in men based on data from a health insurance company database. METHODS: 
The prescription-based database of the largest health insurance company of the Czech 
Republic (VZP CR) that covers about 65% of the Czech population was used as a 
source of data from 2002–2006. Health insurance is compulsory under Czech law. 
An insured male person with a recorded prescription for OPM (alendronate, risedro-
nate, calcitonin, strontium ranelate) in the year of interest was deﬁned as a patient 
and an insured male person with a recorded prescription for OPM in the years border-
ing the year of interest was deﬁned as a chronically treated patient. For the year of 
interest, the percentages of chronically treated patients without OPM medication as 
well as those with very low, i.e. 122 deﬁned daily doses (DDD)/year, low (122–243 
DDD/year) and adequate (243 DDD/year) medication adherence were determined. 
RESULTS: In 2002–2006, men accounted for less than 5% of OPM consumers. The 
total OPM and alendronate consumption rates were 0.6 and 0.3 DDD/1000 insured 
male persons/day, respectively. The number of male patients on alendronate more than 
doubled to 1123 in 2006. As many as 52% and 64% of the chronically treated patients 
fell into the adequate medication adherence group in 2004 and 2005, respectively. 
CONCLUSIONS: Signals of insufﬁcient osteoporosis treatment in the Czech male 
population were found. The increasing adequate medication adherence among the 
